ATLANTA, July 8, 2026 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living with myasthenia gravis (MG) or supporting a loved one impacted by the disease. The scholarship program reflects UCB’s continued commitment to supporting the MG community beyond medicine by helping reduce the financial burden associated with pursuing higher education and career development.

This year’s recipients have demonstrated leadership, service, and perseverance far beyond the classroom. Among them are individuals who have served as rare disease and MG advocates, participated in community awareness efforts, volunteered with patient organizations, led service initiatives, and contributed to research, education, and peer support programs. Several recipients have balanced their academic ambitions with caregiving responsibilities, employment, and ongoing health challenges, while others have pursued creative, scientific, and civic projects aimed at making a positive impact in their communities. Together, their experiences reflect the strength, determination, and purpose that define the myasthenia gravis community.

Living with a rare disease like MG, or caring for someone who has MG, can present significant physical, emotional, and financial challenges. Through this scholarship program, UCB aims to empower people impacted by MG to continue their education, build new skills, and pursue meaningful career paths.

This year’s scholarship recipients represent a diverse group of passionate, resilient individuals from across the country, including people living with MG as well as family members and caregivers. Recipients include graduating high school seniors, undergraduate and graduate students, and individuals pursuing professional and certification programs in fields ranging from healthcare and science to engineering, public health, social work, and advocacy.

“We continue to be deeply inspired by the stories and the determination of people living with myasthenia gravis,” said Kimberly Moran, SVP & Head, U.S. Rare Diseases, UCB. “This year’s scholarship recipients reflect the ambition and breadth of talent within the MG community. We are committed to making a difference in people’s lives and are proud to support them as they pursue their education, working towards their personal and professional goals and creating impact for those around them.”

“Financial assistance from the UCB Myasthenia Gravis Scholarship will allow me to devote greater focus to academic excellence, but more importantly, it would strengthen my ability to transform personal experience into purposeful impact,” said Cameron T., one of the UCB Myasthenia Gravis Scholarship recipients.

The UCB Myasthenia Gravis Scholarship selection committee is composed of individuals impacted by MG and healthcare professionals specializing in neuromuscular diseases, ensuring that each application is reviewed with both clinical insight and lived experience.

“Being a part of this process provided a real understanding and insight of patients that deepen when we step beyond the clinic walls and truly hear their lived experiences,” said Deena Rodey, APRN, ATC, AQH.

Congratulations to the 2026 UCB Myasthenia Gravis Scholarship Recipients:

• Aleksander – Carmel Valley, California
• Brady G. – Creston, Washington
• Cameron T.
• Delaney N. – Tempe, Arizona
• Elisa R.
• Jodi D. – Seminole, Florida
• Laura C. – Rockfield, Kentucky
• Lily B.
• Michael Shaye V. – Fort Salonga, New York
• Naiya A. – Lauderhill, Florida
• Phoebe M. – Eden Prairie, Minnesota
• Taylor

Note: Recipients’ names are included with their permission. Some recipients opted not to have their names included in this announcement.

To learn more about the UCB Myasthenia Gravis Scholarship program, visit
https://www.ucbmgscholarship.com/.

UCB Myasthenia Gravis Scholarship™ is a trademark of the UCB Group of Companies.
©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-DA-2600018

For further information, contact UCB:
U.S. Communications
Becky Malone
Becky.Malone@ucb.com
T +1-919-605-9600

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA.

About the UCB Myasthenia Gravis Scholarship™ 
The UCB Myasthenia Gravis Scholarship offers educational scholarships to people living with myasthenia gravis and their immediate family members who are pursuing further education, whether continuing their education or gaining new career skills. The scholarship can be used for an associate’s, undergraduate, graduate degree, or specialty/trade school certificate. Scholarship requirements and limitations apply. For more information, please visit www.ucbmgscholarship.com.

Forward-looking statements
This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-DA-2500185

View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-awards-annual-myasthenia-gravis-scholarships-to-15-individuals-impacted-by-mg-in-the-us-302820785.html

SOURCE UCB